# Validation Master Plan - OncoSML mRNA Vaccine System

**Document ID:** SML-VMP-001  
**Version:** 1.0  
**Effective Date:** 2026-04-06  
**Classification:** GMP-Controlled Document  

---

## 1. Introduction

### 1.1 Purpose
This Validation Master Plan (VMP) defines the overall strategy, scope, and approach for validating the OncoSML mRNA Vaccine System for clinical trial use. The validation ensures the system consistently produces results meeting predetermined specifications and quality attributes.

### 1.2 Scope
This VMP covers:
- Software validation (GAMP 5 Category 4)
- Infrastructure validation
- Process validation
- Data integrity validation
- Security validation

### 1.3 Objectives
- Ensure patient safety and data integrity
- Comply with FDA 21 CFR Part 11, EU Annex 11, and ICH Q9
- Demonstrate system fitness for intended use
- Provide documented evidence of validation

---

## 2. System Description

### 2.1 System Overview
The OncoSML mRNA Vaccine System is a comprehensive software platform for:
- Neoantigen prediction and selection
- mRNA sequence optimization
- Clinical trial readiness assessment
- Pharmacokinetics modeling
- Regulatory report generation

### 2.2 System Architecture
```
┌─────────────────────────────────────────────────────────────┐
│                     Presentation Layer                       │
│                    (Web Dashboard/API)                       │
├─────────────────────────────────────────────────────────────┤
│                     Application Layer                        │
│  ┌─────────────┐ ┌─────────────┐ ┌─────────────┐            │
│  │Immunogenicity│ │HLA Binding  │ │mRNA Optim.  │            │
│  │   Engine    │ │  Predictor  │ │  Designer   │            │
│  └─────────────┘ └─────────────┘ └─────────────┘            │
│  ┌─────────────┐ ┌─────────────┐ ┌─────────────┐            │
│  │     PK      │ │  Clinical   │ │   Report    │            │
│  │  Modeling   │ │  Validator  │ │  Generator  │            │
│  └─────────────┘ └─────────────┘ └─────────────┘            │
├─────────────────────────────────────────────────────────────┤
│                      Data Layer                              │
│  ┌─────────────┐ ┌─────────────┐ ┌─────────────┐            │
│  │  PostgreSQL │ │Audit Trail  │ │   Backup    │            │
│  │  Database   │ │   Store     │ │  Storage    │            │
│  └─────────────┘ └─────────────┘ └─────────────┘            │
└─────────────────────────────────────────────────────────────┘
```

### 2.3 Modules
1. **Immunogenicity Engine** - Neoantigen scoring and prediction
2. **HLA Binding Predictor** - MHC-peptide binding affinity
3. **mRNA Optimizer** - Sequence optimization and design
4. **PK Modeler** - Pharmacokinetics simulation
5. **Clinical Validator** - Trial readiness assessment
6. **Report Generator** - Regulatory document generation

---

## 3. Validation Approach

### 3.1 GAMP 5 Category
**Category 4: Configured Product**
- The system is a configured software product
- Requires full validation lifecycle
- Risk-based approach applied

### 3.2 Validation Lifecycle
```
┌──────────────┐    ┌──────────────┐    ┌──────────────┐
│   Concept    │ →  │    Project   │ →  │  Operation   │
│   Definition │    │   Execution  │    │   & Maintain │
└──────────────┘    └──────────────┘    └──────────────┘
       │                   │                   │
       ▼                   ▼                   ▼
┌──────────────┐    ┌──────────────┐    ┌──────────────┐
│ User Requirements│ │IQ/OQ/PQ     │    │Periodic     │
│ Specification │    │Testing      │    │Reviews      │
└──────────────┘    └──────────────┘    └──────────────┘
```

### 3.3 Validation Strategy
- **Risk-based testing** - Focus on critical functions
- **Incremental validation** - Module-by-module approach
- **Automated testing** - Where possible for repeatability
- **Manual testing** - For complex workflows

---

## 4. Organizational Responsibilities

### 4.1 Validation Team

| Role | Responsibilities | Assigned To |
|------|-----------------|-------------|
| Validation Owner | Overall accountability | TBD |
| QA Representative | Quality oversight | TBD |
| Software Engineer | Technical implementation | TBD |
| Clinical Affairs | Regulatory compliance | TBD |
| IT/Security | Infrastructure security | TBD |
| End User Representative | User acceptance testing | TBD |

### 4.2 Responsibilities Matrix

| Activity | Validation Owner | QA | Software Eng | Clinical |
|----------|-----------------|-----|--------------|----------|
| VMP Approval | A | C | I | I |
| Requirements | R | C | R | C |
| Test Planning | R | C | R | I |
| Test Execution | I | A | R | C |
| Deviation Review | C | A | I | I |
| Final Approval | A | A | I | I |

*A=Accountable, R=Responsible, C=Consulted, I=Informed*

---

## 5. Deliverables

### 5.1 Validation Documents

| Document ID | Document Name | Version | Status |
|-------------|---------------|---------|--------|
| SML-VMP-001 | Validation Master Plan | 1.0 | Draft |
| SML-URS-001 | User Requirements Specification | 1.0 | Draft |
| SML-DS-001 | Design Specification | 1.0 | Draft |
| SML-RA-001 | Risk Assessment | 1.0 | Draft |
| SML-IQ-001 | Installation Qualification | 1.0 | Draft |
| SML-OQ-001 | Operational Qualification | 1.0 | Draft |
| SML-PQ-001 | Performance Qualification | 1.0 | Draft |
| SML-VSR-001 | Validation Summary Report | 1.0 | Draft |

### 5.2 Standard Operating Procedures

| SOP ID | SOP Name | Version | Status |
|--------|----------|---------|--------|
| SOP-001 | Software Development | 1.0 | Draft |
| SOP-002 | Change Control | 1.0 | Draft |
| SOP-003 | Document Control | 1.0 | Draft |
| SOP-004 | Training | 1.0 | Draft |
| SOP-005 | Incident Management | 1.0 | Draft |
| SOP-006 | Backup & Restore | 1.0 | Draft |
| SOP-007 | Audit Trail Review | 1.0 | Draft |
| SOP-008 | Access Control | 1.0 | Draft |

---

## 6. Risk Assessment

### 6.1 Risk Matrix

| Severity | Minor | Moderate | Major | Critical |
|----------|-------|----------|-------|----------|
| Probable | Medium | High | High | Critical |
| Occasional | Low | Medium | High | High |
| Remote | Low | Low | Medium | High |
| Unlikely | Low | Low | Low | Medium |

### 6.2 Risk Categories

#### Patient Safety Risks
- **Incorrect neoantigen selection** → Ineffective treatment
- **Wrong dosage calculation** → Safety concerns
- **Data corruption** → Wrong patient treatment

#### Data Integrity Risks
- **Unauthorized data modification** → Regulatory non-compliance
- **Data loss** → Trial compromise
- **Audit trail gaps** → Inspection findings

#### Security Risks
- **Unauthorized access** → PHI breach
- **Data interception** → Privacy violation
- **System compromise** → Service disruption

### 6.3 Risk Mitigation

| Risk | Mitigation Strategy |
|------|---------------------|
| Incorrect predictions | Algorithm validation, peer review |
| Data corruption | Checksums, backup, audit trails |
| Unauthorized access | RBAC, MFA, encryption |
| System failure | HA configuration, DR plan |

---

## 7. Validation Schedule

### 7.1 Timeline

| Phase | Start Date | End Date | Duration |
|-------|------------|----------|----------|
| Planning | Week 1 | Week 2 | 2 weeks |
| Requirements | Week 2 | Week 4 | 3 weeks |
| Design | Week 4 | Week 6 | 3 weeks |
| Development | Week 6 | Week 12 | 7 weeks |
| IQ | Week 13 | Week 14 | 2 weeks |
| OQ | Week 14 | Week 17 | 4 weeks |
| PQ | Week 17 | Week 20 | 4 weeks |
| Reporting | Week 20 | Week 24 | 5 weeks |

### 7.2 Milestones

- **M1:** VMP Approval - Week 2
- **M2:** URS Approval - Week 4
- **M3:** Design Review - Week 6
- **M4:** Code Complete - Week 12
- **M5:** IQ Complete - Week 14
- **M6:** OQ Complete - Week 17
- **M7:** PQ Complete - Week 20
- **M8:** Validation Complete - Week 24

---

## 8. Change Control

### 8.1 Change Categories

| Category | Description | Approval Required |
|----------|-------------|-------------------|
| Minor | Documentation typos | QA Manager |
| Moderate | Bug fixes, non-critical | Validation Owner + QA |
| Major | Feature changes | Validation Board |
| Critical | Architecture changes | Full re-validation |

### 8.2 Change Control Process
1. Change Request submitted
2. Impact Assessment performed
3. Approval obtained
4. Implementation completed
5. Testing performed
6. Documentation updated
7. Change closed

---

## 9. Deviation Management

### 9.1 Deviation Categories

| Category | Description | Action |
|----------|-------------|--------|
| Critical | Affects patient safety | Stop, investigate, re-validate |
| Major | Affects data integrity | Investigate, CAPA, document |
| Minor | Administrative issue | Document, correct |

### 9.2 Deviation Process
1. Deviation identified and documented
2. Impact assessment performed
3. Root cause analysis conducted
4. CAPA implemented
5. Effectiveness verified
6. Deviation closed

---

## 10. Training

### 10.1 Training Requirements

| Role | Training Required |
|------|-------------------|
| Administrators | System administration, security |
| End Users | System operation, data entry |
| QA Personnel | Audit procedures, compliance |
| IT Staff | Infrastructure, backup/restore |

### 10.2 Training Records
- Training attendance logs
- Competency assessments
- Training effectiveness evaluation
- Refresher training schedule

---

## 11. Appendices

### Appendix A: Glossary

| Term | Definition |
|------|------------|
| ALCOA+ | Attributable, Legible, Contemporaneous, Original, Accurate + |
| CAPA | Corrective and Preventive Action |
| GAMP | Good Automated Manufacturing Practice |
| GMP | Good Manufacturing Practice |
| IQ/OQ/PQ | Installation/Operational/Performance Qualification |
| PHI | Protected Health Information |
| RBAC | Role-Based Access Control |
| SOP | Standard Operating Procedure |
| VMP | Validation Master Plan |
| URS | User Requirements Specification |

### Appendix B: References

1. FDA 21 CFR Part 11 - Electronic Records and Signatures
2. EU Annex 11 - Computerised Systems
3. ICH Q9 - Quality Risk Management
4. GAMP 5 - A Risk-Based Approach to Compliant GxP Computerized Systems
5. ISO 14971 - Application of Risk Management to Medical Devices
6. IEC 62304 - Medical Device Software Lifecycle Processes

---

## 12. Approval

**Prepared By:** ___________________ Date: _________

**Reviewed By (QA):** ___________________ Date: _________

**Approved By (Management):** ___________________ Date: _________

---

*This document is controlled under the Quality Management System. Unauthorized copying or distribution is prohibited.*